Publications / Eng

To consult documents published before 2015, please see Publications (archives 2005-2014).

Clinical Intervention Models (CIM)

Note: In this sub-section, the documents are listed in alphabetical order.

5-azacitidine use in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2015

Abbreviations and symbols used on prescriptions in Quebec’s University Teaching hospitals – CIM, descriptive analysis,  2016

Surgical Antibiotic Prophylaxis in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2014

Antifungals – Treatment of Yeast Fungemia and Candidemia – Treatment Algorithm (August 2019 version):

Antifungal use in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2017

Anti-PD-1: Descriptive analysis of the use of anti-PD-1 antibodies in cancer patients in Québec’s university teaching hospitals – CIM, descriptive analysis, 2020

Biosimilars: State of Knowledge and Recommendations for Quebec’s University Teaching  Hospitals – CIM, comprehensive evaluation, 2017

Bortezomib use in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2015

Dexmedetomidine use in intensive care in Quebec’s University Teaching Hospitals based on the utilization criteria established by the TDMP in 2010 – CIM, descriptive analysis, 2010

The use of Filgrastim in Quebec’s university teaching hospitals (UTHs) – CIM, descriptive analysis, 2018

Descriptive analysis of the pediatric use of filgrastim in Quebec’s university teaching hospitals (UTHs) – CIM, descriptive analysis, 2018

Ipilimumab in the Treatment of Metastatic or Unresectable Advanced Melanoma in Quebec’s University Teaching Hospitals – CIM, descriptive analysis, 2016

Evaluation of micafungin (Mycamine™) for the treatment and prevention of Candida infections in pediatric patients – CIM, summary evaluation 2018 – Updated december 2020

Nivolumab (Opdivo™) – What is the preferred strategy: a weight-based dosage, a fixed dose or a weight-based dosage with a maximum dose? – CIM, summary evaluation 2018

Pertuzumab/trastuzumab in HER-2 positive metastatic breast cancer – CIM, descriptive analysis, 2019

Pembrolizumab (Keytruda™) – What is the preferred strategy: a weight-based dosage, a fixed dose, or a weight-based dosage with a maximum dose? – CIM, summary evaluation 2018

Prescribing and use of Rituximab as Maintenance Therapy for Follicular Lymphoma in Quebec’s University Teaching Hospitals – CIM, summary evaluation 2013

Sugammadex – CIM, descriptive analysis, 2020

Posters

Postsurgical Discharge Prescriptions for Opioid-naive Pediatric Patients in Four University Teaching Hospitals in Quebec: A Descriptive Analysis presented at the Canadian Society of Hospital Pharmacists (CSHP) in Niagara Falls – April 2024

Retrospective Cohort Analysis of Sotrovimab and Remdesivir Use in Ambulatory Patients with COVID-19 in Five Teaching Hospitals in Quebec, Canada presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Copenhagen – April 2023

Descriptive Analysis of first-line non-small cell Lung cancer treatment with Pembrolizumab in tumors expressing PD-L1 ≥ 50% in patients treated in five Québec’s university teaching hospitals (DALP-First study) presented at the Canadian Association of Pharmacy in Oncology (CAPhO) Conference in Toronto – April 2023

Postsurgical Discharge Prescriptions for Opioid-naive Patients in University Teaching Hospitals in Quebec: A Descriptive Analysis presented at the Canadian Society of Hospital Pharmacists (CSHP) in Banff – March 2023

Descriptive Analysis of Anti-PD-1 Use in Four Adult University Teaching Hospitals in Québec, Canada. – CAPhO, April 2020, Toronto Online – Video presentation of the poster

Descriptive Analysis of Pertuzumab use in Metastatic Breast Cancer (MCB) in four adult University Teaching Hospital inQuébec, Canada: Data after four years of follow-up. – CAPhO, April 2020, Toronto Online – Video presentation of the poster

Descriptive Analysis of Filgrastim Use in Children in Four University Teaching Hospitals in Québec, Canada – CAPhO, Halifax, April 2019

A clinical intervention model for knowledge transfer: Treatment of candidemia – ACMTS, Edmonton, April 2019

Descriptive Analysis of Filgrastim Use in Four Adult University Teaching Hospital in Quebec – CAPhO, Ottawa-Gatineau, May 2018

Biosimilars : State of knowledge and recommendation from the Programme de gestion thérapeutique des médicaments  – ACMTS, Halifax, April 2018

Descriptive Analysis of antifungals use in five university teaching hospitals in Quebec – ASM Microbe, June 2017

5-Azacitidine descriptive analysis – CAPhO, Niagara Falls, April 2016

Bortezomib descriptive analysis – CAPhO, Niagara Falls, April 2016

Descriptive analysis and utilization review of meropenem in five university teaching hospitals – ICAAC, September 2011 

Journal articles / abstracts

Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study). Journal article published in Current Oncology – March 2023

Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada. Abstract published in Journal of Clinical Oncology – May 2019

Descriptive analysis of the use of ipilimumab (IPI) in previously treated patients with unresectable stage III or IV metastatic melanoma (MM) in four university hospitals of Quebec, Canada. Abstract published in Journal of Clinical Oncology – May 2016

Descriptive Analysis of Azacitidine Use in Four Adult University Teaching Hospitals in Quebec, Canada. Abstract published in Blood (journal) – December 2015

Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada. Abstract published in Blood (journal) – December 2015